Atypical Hemolytic-Uremic Syndrome (aHUS) Registry

The study will capture post-marketing safety data on patients treated with eculizumab.
Additionally, the study will collect information on the progression of disease in all
patients.

Inclusion Criteria:

- Male or female patients of any age, including minors, who have been diagnosed with
aHUS

- Able to give written informed consent. Patient or patient's parent/legal guardian must
be willing and able to given written informed consent and the patient (if minor) must
be willing to give written informed assent [if applicable as determined by the central
Institutional Review Boards/Independent Ethics Committees (IRB/IEC)].

- ADAMTS13 > 5%, if performed.

Exclusion Criteria:

- Hemolytic Uremic Syndrome (HUS) only due to Shiga Toxin